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Simple Summary: Primary gastrointestinal T/NK cell lymphoma (GI-TNKL) is a heterogeneous
group including various subtypes, anatomic locations, and clinicopathologic features. GI-TNKL is
difficult to diagnose due to its rarity, various subtypes, and histopathological features. We performed
a retrospective analysis of 38 cases of GI-TNKL in South Korea. GI-TNKL consisted of unique
subtypes showing specific characteristics of macroscopy, histology, immunophenotype, and prevalent
anatomic subsites. ENKTL and MEITL were relatively common. GI-TNKL showed aggressive
behavior with short PFS and OS. This clinical and pathological descriptive analysis will be helpful
for accurate understanding, diagnosis, and treatment.
Abstract: Primary gastrointestinal T/NK cell lymphoma (GI-TNKL) is an uncommon and hetero-
geneous group of lymphoid malignancies. We aimed to investigate their subtype distribution,
clinicopathologic characteristics, and clinical outcomes. A total of 38 GI-TNKL cases and their clinical
and pathological characteristics were analyzed. GI-TNKL occurred in adults with a median patient
age in the sixth decade of life and showed a slight male predominance. The most common histologic
type was extranodal NK/T-cell lymphoma, nasal type (ENKTL; 34.2%), followed by monomorphic
epitheliotropic intestinal T-cell lymphoma (MEITL; 31.6%), intestinal T-cell lymphoma, NOS (ITCL,
NOS, 18.4%), anaplastic large cell lymphoma, ALK-negative (ALCL, ALK-; 13.2%). The small intes-
tine was the primary affected region. More than 90% of patients complained of various GI symptoms
and cases with advanced Lugano stage, high IPI score, or bowel perforation that required emergent
operation were not uncommon. GI-TNKL also showed aggressive behavior with short progression-
free survival and overall survival. This thorough clinical and pathological descriptive analysis will
be helpful for accurate understanding, diagnosis, and treatment.
Keywords: T/NK cell lymphoma; gastrointestinal tract; intestinal lymphoma; clinicopathologic features
1. Introduction
The gastrointestinal tract is the most common site of extranodal lymphomas and
primary gastrointestinal lymphomas are mostly of B cell lineage. Primary gastrointestinal
T/NK cell lymphoma (GI-TNKL) is generally rare, but is relatively more common in East
Asia where it accounts for 13–15% of primary GI lymphoma [1–4]. GI-TNKL is a heteroge-
neous group including various subtypes, anatomic locations, and clinicopathologic features.
The revised fourth edition of the World Health Organization (WHO) classification recently
included enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic
intestinal T-cell lymphoma (MEITL), intestinal T-cell lymphoma, NOS (ITCL, NOS), and in-
dolent T-cell lymphoproliferative disorder of the GI tract in the new category ‘intestinal
T-cell lymphoma’ [5]. In addition, extranodal NK/T-cell lymphoma, nasal type (ENKTL)
and anaplastic large cell lymphoma (ALCL) often occur in the GI tract. EATL is the most
common GI-TNKL in Western countries because it occurs in individuals with celiac disease,
but it is extremely rare in Asia [6]. Except for indolent T-cell lymphoproliferative disorder
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of the GI tract, GI-TNKL is usually aggressive and is frequently accompanied by GI compli-
cations such as bowel perforation, obstruction, and bleeding, which increase morbidity and
mortality [7,8]. There have been few specific studies on T/NK cell lymphoma primarily
developed in the GI tract. In this study, we performed a retrospective analysis of 38 cases
in South Korea to improve the knowledge of clinicopathologic features of GI-TNKL.
2. Materials and Methods
2.1. Patient Selection and Histological Review
Primary gastrointestinal lymphoma was defined as predominant lesions in the ali-
mentary tract with or without regional lymph node involvement [9]. We excluded post-
transplant lymphoproliferative disorder and indolent T-cell lymphoproliferative disorder
of the GI tract. A total of 38 primary gastrointestinal T/NK cell lymphoma (GI-TNKL)
cases were retrieved from Severance Hospital and National Health Insurance Service Ilsan
Hospital from January 2005 to December 2017. All hematoxylin and eosin-stained and
immunostained slides were reviewed by experienced hematopathologists (S.O.Y., W.I.Y.,
and E.K.K.) and histologic classification was undertaken according to the revised fourth
edition of the WHO classification of neoplastic disease of hematopoietic and lymphoid
tissue [5]. Cases showing the histology of peripheral T cell lymphoma, not otherwise speci-
fied (PTCL, NOS), which primarily involves the GI tract but could not be categorized as
MEITL or other T/NK cell lymphoma subtypes, were defined as intestinal T cell lymphoma,
not otherwise specified (ITCL, NOS). Clinical information and survival data including
serum lactate dehydrogenase (LDH), β-2 microglobulin (B2M), Eastern Cooperative Oncol-
ogy Group (ECOG) performance status, international prognostic index (IPI), and findings
of imaging studies and endoscopy were obtained by review of medical records. Patients
were staged according to the Lugano staging system for GI lymphomas [10]. Lugano stage
I is defined as a tumor confined to the GI tract with a single primary site or multiple
noncontiguous lesions. Stage II is a tumor that extends into the abdomen with local or
distant lymph node involvement and stage IIE is defined as a tumor with adjacent or-
gan involvement. Stage IV is defined as disseminated extranodal disease or concurrent
supradiaphragmatic nodal involvement. Details for the ancillary tests are summarized in
Supplementary Data.
2.2. Statistical Analysis
The chi-square, Fisher exact, and one-way ANOVA tests were used to analyze differ-
ences between evaluated variables. Overall survival (OS) was measured from date of initial
diagnosis to date of death or last follow-up. Progression-free survival (PFS) was measured
from the date of initial diagnosis to that of disease recurrence, progressive disease without
complete remission, or disease-related death during the study period. The Kaplan-Meier
method was used to analyze survival rates, and differences therein were compared us-
ing the log-rank test. Two-sided p values < 0.05 were considered statistically significant.
Multivariate analysis was performed with the Cox proportional hazard model. Statistical
analyses were conducted using IBM SPSS 23 software for Windows (IBM Corp., Armonk,
NY, USA).
3. Results
3.1. Clinicopathologic Characteristics of Primary Gastrointestinal T/NK Cell Lymphoma
Among 836 primary GI lymphoma cases diagnosed from 2005 to 2017, mature B cell
lymphomas accounted for the majority (797 cases, 95.3%). Primary GI mature B cell lym-
phoma mainly consisted of extranodal marginal zone lymphoma of mucosa-associated lym-
phoid tissue (MALT) type (399 cases, 50.1%) and diffuse large B cell lymphoma (310 cases,
38.9%). Among the primary GI lymphomas, 356 cases (43.7%) were gastric MALT lym-
phoma. T/NK cell lymphomas were 38 cases, accounting for 4.5% (38/836) of all primary
GI lymphomas and 8.1% (38/471) when gastric MALT lymphomas were excluded.
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Clinicopathologic characteristics of these patients with GI-TNKL are summarized
in Table 1. The median age was 58 years (range, 34 to 84), and the male to female ratio
was 1.4:1. The most common histologic type was ENKTL (n = 13, 34.2%), followed by
MEITL (n = 12, 31.6%), ITCL, NOS (n = 7, 18.4%), ALCL, ALK- (n = 5, 13.2%), and ALCL,
ALK+ (n = 1, 2.6%). The most frequently affected anatomic location was the small intestine
(71.1%), followed by large intestine (34.2%), stomach (23.7%), ileocecum (13.2%), and esoph-
agus (2.6%). Multiple site involvement was found in 31.6% of patients. Most patients had
symptoms, with abdominal pain and discomfort being the most common complaint at the
initial presentation, followed by weight loss and poor oral intake, diarrhea, and GI bleeding.
GI complications developed in 63.2% during the disease, including perforation, hemor-
rhage, fistula formation, and obstruction. Lugano stage was advanced (stage IV) in 47.4%
of patients and others were stage I or II. IPI score was 3 or more (high or high-intermediate)
in 31.6%, and 7.9% presented ECOG performance status 2 or more.
Table 1. Clinicopathologic characteristics of 38 patients with primary gastrointestinal T/NK cell lymphoma.
Characteristics n (%)
Median age (range) 58 years (34–84)




ITCL, NOS 7 (18.4)
ALCL, ALK- 5 (13.2)













Multiple site involvement 12 (31.6)
Initial presentation
Abdominal pain and discomfort 20 (52.6)
Weight loss and poor oral intake 8 (21.1)
Diarrhea 7 (18.4)
GI bleeding 5 (13.2)
Vomiting 3 (7.9)
No symptom 2 (5.3)
GI complication 24 (63.2)
Perforation 15 (39.5)
Hemorrhage 4 (10.5)
Fistula formation 3 (7.9)
Obstruction 2 (5.3)





ECOG performance status ≥ 2 3/34 (7.9)
IPI score ≥ 3 12 (31.6)
Anemia 21 (55.3)






Endoscopic biopsy 19 (50)
Surgery 19 (50)
First treatment
Surgery with adjuvant therapy 15 (39.5)
Non-surgical therapy 14 (36.8)
Surgery 4 (10.5)
Unknown 5 (13.2)
First line non-surgical treatment 29
CTx alone 24 (82.8)
CTx + autoPBSCT 3 (10.3)
CTx + RTx + autoPBSCT 1 (3.5)
RTx + CTx 1 (3.4)
ALCL, ALK-; anaplastic large cell lymphoma, ALK-negative, ALCL, ALK+; anaplastic large cell lymphoma,
ALK-positive, autoPBSCT; autologous peripheral blood stem cell transplantation, ECOG; Eastern Cooperative
Oncology Group, ENKTL; extranodal NK/T cell lymphoma, nasal type, GI; gastrointestinal tract, IPI; Interna-
tional prognostic index, ITCL, NOS; intestinal T-cell lymphoma, not otherwise specified, MEITL; monomorphic
epitheliotropic intestinal T-cell lymphoma, RTx; radiation therapy.
Fifty percent of patients were diagnosed by surgical resection and nine patients (23.7%)
underwent emergency surgery. Excluding five patients who could not confirm specific
treatment methods and four patients who died at the time of hospitalization after the
first diagnosis and surgery, 15 patients (39.5%) received both surgery and non-surgical
treatment, and the remaining patients (n = 14, 36.8%) received non-surgical treatment as
the first line therapy. Of the 29 patients who received first-line chemotherapy, four received
autologous peripheral blood stem cell transplantation, and two received radiation therapy.
CHOP (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone)
with or without etoposide was the most common first-line drugs, followed by IMVP-16PL
(ifosfamide, methotrexate, etoposide, cyclophosphamide, and dexamethasone; Supplemen-
tary Table S1). Eighteen patients (47.4%) died while receiving first-line treatment, or died
without second-line treatment after progression or recurrence.
3.2. Comparison of Clinical Features of Primary Gastrointestinal T/NK Cell Lymphoma Subtypes
Comparisons of clinical features of GI-TNKL subtypes are presented in Table 2 and
Supplementary Figure S1. The small intestine was the most frequent main location in
ENKTL, MEITL, and ITCL, NOS (p = 0.002). Esophageal or gastric involvement was more
common in ALCL and the least common in MEITL (p = 0.003). When endoscopic examina-
tion was possible or when the lesion was endoscopically visible, it appeared as a single or
multiple mass, deep ulcer, superficial ulcer, or relatively normal. Mass lesion was the most
common finding (Table 3). GI complication during the course of the disease appeared fre-
quently in ENKTL and MEITL (p = 0.074). Perforation most frequently occurred in ENKTL,
followed by MEITL (p = 0.026). Advanced stage was most frequent in ENKTL patients
(p = 0.085). For initial diagnosis or treatment, ENKTL, MEITL, and ITCL, NOS were more
likely to have a surgical procedure used, whereas non-surgical methods were mainly used
for ALCL (p = 0.009). Treatment response for initial chemotherapy showed complete remis-
sion (CR) in 53.6% and progressive disease (PD) in 21.4%. ENKTL showed the highest CR
rate and also PD rate (p = 0.564). One case, a 34-year-old male patient, had ALCL, ALK+ at
the stomach and showed complete initial chemotherapy response without recurrence.
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Table 2. Comparison of clinical features of primary gastrointestinal T/NK cell lymphoma subtypes.
Variable









(18.4%) n = 5 (13.2%) n = 1 (2.6%)
Age > 60 13 (34.2) 5 (38.5) 2 (16.7) 4 (57.1) 2 (40) 0 (0) 0.882
Mean age 58.3 58.9 55.5 62 63 34 0.297
Sex Male 22 (57.9) 9 (69.2) 6 (50) 3 (42.9) 3 (60) 1 (100) 0.777
Female 16 (42.1) 4 (30.8) 6 (50) 4 (57.1) 2 (40) 0 (0)
Main-location
Esophagus 1 (2.6) 0 (0) 0 (0) 0 (0) 1 (20) 0 (0) 0.002
Stomach 9 (23.7) 2 (15.4) 1 (8.3) 2 (28.6) 3 (60) 1 (100)
SI 17 (44.7) 5 (38.5) 9 (75) 3 (42.9) 1 (20) 0 (0)
IC 7 (18.4) 2 (15.4) 0 (0) 2 (28.6) 0 (0) 0 (0)
LI 4 (10.5) 4 (30.8) 2 (16.7) 0 (0) 0 (0) 0 (0)
Esophageal/gastric involvement 10 (26.3) 2 (15.4) 1 (8.3) 2 (28.6) 4 (80) 1 (100) 0.003
Multiple site involvement 13 (34.2) 4 (30.8) 5 (41.7) 3 (42.9) 1 (20) 0 (0) 0.767
GI complication 24 (63.2) 10 (76.9) 8 (66.7) 4 (57.1) 2 (40) 0 (0) 0.074
GI perforation 15 (39.5) 8 (61.5) 5 (41.7) 1 (14.3) 1 (20) 0 (0) 0.026
Lugano stage I/II 20 (52.6) 5 (38.5) 6 (50) 4 (57.1) 4 (80) 1 (100) 0.085IV 18 (47.4) 8 (61.5) 6 (50) 3 (42.9) 1 (20) 0 (0)
Elevated serum LDH level 17/36 (42.7) 5/11 (45.5) 5 (45.5) 4 (57.1) 2 (40) 1 (100) 0.663
Elevated serum B2M level 22/30 (73.3) 7/8 (87.5) 7/11 (63.6) 4/6 (66.7) 3/4 (75) 1 (100) 0.857
IPI score ≥ 3 12 (31.6) 5 (38.5) 4 (33.3) 2 (28.6) 1 (20) 0 (0) 0.365
Initial treatment
OP ±
CTx/RTx 23 (62.2) 10 (83.3) 8 (66.7) 4 (57.1) 1 (20) 0 (0) 0.009
CTx/RTx 14 (37.8) 2 (16.7) 4 (33.3) 3 (42.9) 4 (80) 1 (100)
CTx response
CR 15/28 (53.6) 5/8 (62.5) 5/10 (50) 3/6 (50) 1/3 (33.3) 1 (100) 0.486
PR 6/28 (21.4) 0/8 (0) 3/10 (30) 1/6 (16.7) 2/3 (66.7) 0 (0)
SD 1/28 (3.6) 0/8 (0) 0/10 (0) 1/6 (16.7) 0/3 (0) 0 (0)
PD 5/28 (21.4) 3/8 (37.5) 2/10 (20) 1/6 (16.7) 0/3 (0) 0 (0)
Recurrence/progression 32 (84.2) 9 (69.2) 12 (100) 6 (85.7) 5 (100) 0 (0) 0.116
Median OS (months) 9.6 5.1 11.2 16.6 9.6 - 0.829
Median PFS (months) 5.1 3.8 5.8 7.7 2.8 - 0.844
ALCL, ALK-; anaplastic large cell lymphoma, ALK-negative, ALCL, ALK+; anaplastic large cell lymphoma, ALK-positive, B2M; beta-2 mi-
croglobulin, CR; complete response, CTx; chemotherapy, ENKTL; extranodal NK/T cell lymphoma, nasal type, GI; gastrointestinal tract,
IC; ileocecum, IPI; International prognostic index, ITCL, NOS; intestinal T-cell lymphoma, not otherwise specified, LDH; lactate dehy-
drogenase, LI; large intestine, MEITL; monomorphic epitheliotropic intestinal T-cell lymphoma, OP; operation, OS; overall survival, PD;
progressive disease, PFS; progression-free survival, PR; partial response, SD; stable disease, SI; small intestine. Statistically significant
values were boldfaced.
Table 3. Comparison of endoscopic and pathological features of primary gastrointestinal T/NK cell lymphoma subtypes.
Variable
Total ENKTL MEITL ITCL, NOS ALCL, ALK- ALCL, ALK+
n = 38 n = 13 n = 12 n = 7 n = 5 n = 1
Endoscopy
Mass 10/21 (47.6) 2/6 (33.3) 2/5 (40) 2/5 (40) 3/4 (75) 1 (100)
Deep ulcer 5/21 (23.8) 3/6 (50) 0/5 (0) 1/5 (20) 1/4 (25) 0 (0)
Superficial ulcer 5/21 (23.8) 1/6 (16.7) 2/5 (40) 2/5 (40) 0/4 (0) 0 (0)
Normal 1/21 (4.8) 0/6 (0) 1/5 (20) 0/5 (0) 0/4 (0) 0 (0)
Depth of invasion
Mucosa/submucosa 0/19 (0) 0/7 (0) 0/8 (0) 0/3 (0) 0/1 (0) -
Muscularis propria 2/19 (10.5) 0/7 (0) 1/8 (12.5) 0/3 (0) 1/1 (100) -
Subserosa/serosa 17/19 (89.5) 7/7 (100) 7/8 (87.5) 3/3 (100) 0/1 (0) -
Regional lymph node
involvement 24 (63.2) 10 (76.9) 6 (50) 5 (71.4) 2 (40) 1 (100)
Cell size
Small to medium 3 (7.9) 1 (7.7) 2 (16.7) 0 (0) 0 (0) 0 (0)
Medium to large 26 (68.4) 10 (76.9) 10 (83.3) 5 (71.4) 2 (40) 0 (0)
Large pleomorphic 9 (23.7) 2 (15.4) 0 (0) 2 (28.6) 3 (60) 1 (100)
Cell shape
Heterogeneous 24/36 (66.7) 13 (100) 0 (0) 5 (71.4) 5 (100) 1 (100)
Monomorphic 12/36 (33.3) 0 (0) 12 (100) 2 (28.6) 0 (0) 0 (0)
Angiocentricity 6/36 (16.7) 6 (46.2) 0 (0) 0 (0) 0 (0) 0 (0)
Epitheliotropism 12/36 (33.3) 0 (0) 12 (100) 0 (0) 0 (0) 0 (0)
CD3 37 (97.4) 13 (100) 12 (100) 7 (100) 4 (80) 1 (100)
CD4 9/25 (36) 2/8 (25) 1/9 (11.1) 4/5 (80) 2/3 (66.7) -
CD8 15/26 (57.7) 3/9 (33.3) 8/11 (72.7) 4/5 (80) 0/2 (0) -
CD10 1/15 (6.7) 0/6 (0) 0/5 (0) 0/1 (0) 1/2 (50) 0 (0)
CD30 12/33 (36.4) 4/11 (36.4) 1/8 (12.5) 1/5 (20) 5 (100) 1 (100)
CD56 21/36 (58.3) 9 (69.2) 11 (91.7) 1 (14.3) 0/4 (0) -
CD103 6/19 (31.6) 0/5 (0) 6/10 (60) 0/2 (0) 0/2 (0) -
Granzyme B 28/33 (50.9) 10/10 (100) 9/11 (81.8) 5/6 (83.3) 3/5 (6)) 1 (100)
TIA-1 13/18 (72.2) 7/7 (100) 4/6 (66.7) 0/2 (0) 2/3 (66.7) -
PD-1 1/15 (6.7) 0/6 (0) 0/5 (0) 0/2 (0) 1/2 (50) -
ALK 1/16 (6.25) 0/7 (0) 0/5 (0) 0/2 (0) 0 (0) 1 (100)
Ki-67 L.I. (%, average) 70.6 70 83.3 41.7 75 100
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Table 3. Cont.
Variable
Total ENKTL MEITL ITCL, NOS ALCL, ALK- ALCL, ALK+
n = 38 n = 13 n = 12 n = 7 n = 5 n = 1
EBER ISH 9/26 (34.6) 8/8 (100) 0/9 (0) 0/6 (0) 0/3 (0) -
TCR gene rearrange-ment a 8/11 (72.7) 2/5 (40) 5/5 (100) 1/1 (100) - -
TCRG 5/11 1/5 3/5 1/1 - -
TCRB 4/11 1/5 3/5 0/1 - -
TCRD 1/11 0/5 1/5 0/1 - -
ALCL, ALK-; anaplastic large cell lymphoma, ALK-negative, ALCL, ALK+; anaplastic large cell lymphoma, ALK-positive, EBER ISH;
EBV-encoded RNA in situ hybridization, ENKTL; extranodal NK/T cell lymphoma, nasal type, ITCL, NOS; intestinal T-cell lymphoma,
not otherwise specified, L.I.; labeling index, MEITL; monomorphic epitheliotropic intestinal T-cell lymphoma, TCR; T-cell receptor,
a BIOMED-2 based PCR analysis using IdentiClone TCRG, TCRB, and TCRD Gene Clonality Assay Kits (Invivoscribe, CA, USA).
3.3. Morphologic and Immunophenotypic Features of Primary Gastrointestinal T/NK Cell
Lymphoma Subtypes
The morphologic and immunophenotypic features of each lymphoma type are sum-
marized in Table 3 and Figures 1–4. ENKTL appeared as single or multiple infiltrative
masses (33.3%) or ulceration in endoscopy (66.7%; Figure 1A). In resection specimens,
ENKTL grossly appeared with solitary or several ulcerative masses or deep ulcerations
(Figure 1B,C). All seven resection cases involved subserosal or serosal layer infiltration by
tumor cells (Figure 1D,E). Regional lymph nodes were also frequently involved (76.9%).
They usually consisted of medium to large tumor cells and all cases showed heterogeneous
tumor cells (Figure 1F–I). Tumor cells frequently demonstrated a prominent angiocen-
tric and angiodestructive pattern (46.2%, Figure 1F,I), while epitheliotropism was not
found (Figure 1G,H). Background was usually inflammatory or necrotic. Tumor cells
were all immunoreactive for CD3, granzyme B (Figure 1J), and TIA-1; variable for CD56
(69.2%; Figure 2K). They were all reactive in EBER ISH (Figure 1L). Three out of eight
patients (37.5%) who underwent the whole blood EBV quantitative PCR test were positive
(Supplementary Table S2). The average proliferation index was high. A T-cell receptor
(TCR) gene rearrangement study was performed in five cases and two cases had mono-
clonal TCR gene rearrangement.
MEITL endoscopically manifested a mass or a superficial ulcer except for cases with
perforation or jejunal lesion. A case that showed relatively normal appearance in endoscopy
was histologically correlated with intraepithelial lymphocytosis. Most of the cases were
located in the small intestine. Multiple site involvement and perforation were frequent
(Figure 2A,B). Most of the eight resected cases showed transmural involvement and regional
lymph nodes were also frequently involved.
As a definition, almost all cases revealed monomorphic tumor cells (Figure 2C) with
marked epitheliotropism. Large pleomorphic cells were variable admixed (Figure 2D).
Villous architecture was usually distorted and broadened by tumor cells. Tumor cells
commonly spread to the surrounding mucosa with intraepithelial lymphocytosis, and the
villous architecture was relatively preserved (Figure 2E,F). Angiocentricity, inflammatory
background, or prominent tumor necrosis was not observed. Tumor cells were positive
for CD3, CD8 (72.7%; Figure 2G), CD56 (Figure 2H), CD103 (60%), granzyme B (81.8%;
Figure 2I), and TIA-1 (66.7%), while negative for CD20, CD10, PD-1, ALK, and EBER ISH.
Proliferation index was high. TCR gene rearrangement study was performed in five cases
and all had monoclonal TCR gene rearrangement.
Most ITCL, NOS were located in the intestine. ITCL, NOS likely appeared as superfi-
cial ulcer (Figure 3A) or mass (Figure 3B), and frequently revealed transmural involvement.
Tumor cells were medium to large (71.4%) and occasionally showed predominantly large
pleomorphic cells. They were usually heterogeneous with angulated and hyperchromatic
nuclei and a scant amount of eosinophilic cytoplasm (Figure 3C–F). Tumor cells were CD3
positive (Figure 3D) and reactive for both CD4 and CD8. They were mostly positive for
granzyme B (83.3%), occasionally positive for CD30 and CD56. One case showed EBER ISH
positivity in reactive B-cells, not tumor cells. Ki-67 labeling index was variable. A TCR gene
rearrangement study was conducted in one case and showed TCRG clonal rearrangement.
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Figure 1. Primary gastrointestinal extranodal NK/T cell lymphoma, nasal type. Endoscopy reveals a huge ulceroinfiltrative 
lesion with an irregular base in the stomach (A). This case shows multiple hyperemic nodular lesions in the colon (B) and 
small bowel. The small bowel mucosa shows several various sized ulcerations (C). Microscopy shows diffuse transmural 
involvement (D) and a nodular mass in the low power view (E). Angiodestruction and necrosis are frequent findings (F). 
Tumor cells involve mucosa and submucosa and glands are relatively preserved (G). Medium to large atypical lymphoid 
cells infiltrate the lamina propria without epitheliotropism (H). Heterogeneous tumor cells show angiocentric pattern (I). 
Tumor cells are positive for granzyme B (J), CD56 (K), and EBV-encoded small RNA (L). 
MEITL endoscopically manifested a mass or a superficial ulcer except for cases 
with perforation or jejunal lesion. A case that showed relatively normal appearance 
in endoscopy was histologically correlated with intraepithelial lymphocytosis. Most 
Figure 1. Primary gastrointestinal extranodal NK/T cell lymphoma, nasal type. Endoscopy reveals a hug ulceroinfiltrative
lesion with an irregular base in the stomach (A). Thi case shows multiple hyperemic nodular le ions in the colon (B) and
small bowel. The small bowel mucosa shows several various sized ulcerations (C). Microscopy shows diffuse transmural
involvement (D) and a nodular mass in the low power view (E). Angiodestruction and necrosis are frequent findings (F).
Tumor cells involve mucosa and submucosa and glands are relatively preserved (G). Medium to large atypical lymphoid
cells infiltrate the lamina propria without epitheliotropism (H). Heterogeneous tumor cells show angiocentric pattern (I).
Tumor cells are positive for granzyme B (J), CD56 (K), and EBV-encoded small RNA (L).
ALCL, ALK- was mostly located in the stomach rather than the intestine and mani-
fested as a submucosal mass (Figure 4A), an ulcerofungating mass, or deep ulcer. Tumor
cells were medium to large or pleomorphic and heterogeneous. Nuclear membranes were
irregular and occasionally showed hallmark (kidney-shaped) cells and multinucleated
cells. Nuclear chromatin was vesicular or hyperchromatic and eosinophilic cytoplasm
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was scant to abundant (Figure 4B). The background was rich in small vasculature and
inflammatory cells. Tumor cells were all diffusely immunoreactive for CD30 within the
cytoplasm and/or at the cell membrane or in the Golgi area. They were variable for CD3,
CD4, CD10, granzyme B, TIA-1, and PD-1, and negative for CD8, CD56, CD103, ALK,
and EBER ISH. A case of ALCL, ALK+ in the stomach was endoscopically an irregularly
shaped nodular mass (Figure 4C). The biopsy specimen revealed similar histologic features
to ALCL, ALK- (Figure 4D). Tumor cells were positive for CD3 and granzyme B. CD30 was
diffusely positive (Figure 4E) and ALK was also diffusely expressed in cytoplasm and
nuclei (Figure 4F).
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Figure 2. Monomorphic epitheliotropic intestinal T-cell lymphoma. The jejunum shows multiple ulceration with perfora-
tion (A). The transverse colon shows an ulceroinfiltrative mass involving mesenteric lymph nodes (B). Tumor cells are 
monotonous and medium-sized without inflammatory background (C). Some cases show variably admixed large pleo-
morphic cells (D). Tumor cells spread to the surrounding mucosa showing intraepithelial lymphocytosis (E) with rela-
tively preserving villous architecture (F). Tumor cells are positive for CD8 (G), CD56 (H), and granzyme B (I). 
As a definition, almost all cases revealed monomorphic tumor cells (Figure 2C) with 
marked epitheliotropism. Large pleomorphic cells were variable admixed (Figure 2D). 
Villous architecture was usually distorted and broadened by tumor cells. Tumor cells 
commonly spread to the surrounding mucosa with intraepithelial lymphocytosis, and the 
villous architecture was relatively preserved (Figures 2E, F). Angiocentricity, inflamma-
tory background, or prominent tumor necrosis was not observed. Tumor cells were posi-
tive for CD3, CD8 (72.7%; Figure 2G), CD56 (Figure 2H), CD103 (60%), granzyme B (81.8%; 
Figure 2I), and TIA-1 (66.7%), while negative for CD20, CD10, PD-1, ALK, and EBER ISH. 
Proliferation index was high. TCR gene rearrangement study was performed in five cases 
and all had monoclonal TCR gene rearrangement. 
Most ITCL, NOS were located in the intestine. ITCL, NOS likely appeared as super-
ficial ulcer (Figure 3A) or mass (Figure 3B), and frequently revealed transmural involve-
ment. Tumor cells were medium to large (71.4%) and occasionally showed predominantly 
Figure 2. Monomorphic epitheliotropic intestinal T-cell lymphoma. The jejunum shows multiple ulceration with per-
foration (A). The transverse colon shows an ulceroinfiltrative mass involving mesenteric lymph nodes (B). Tumor cells
are monotonous and medium-sized without inflammatory background (C). Some cases show variably admixed large
pleomorphic cells (D). Tumor cells spread to the surrounding mucosa showing intraepithelial lymphocytosis (E) with
relatively preserving villous architecture (F). Tumor cells are positive for CD8 (G), CD56 (H), and granzyme B (I).
3.4. Survival Analysis
The median follow-up time was 10.4 mo ths (rang : 0.1–122.0 months). wenty-nine
patients (76.3%) ied of disease and 32 patients (84.2%) experienced disease recurre ce or
progression during the follow-up period. ALCL, ALK+ cases had no recurrence or death
and were exclu ed from survival analysis. Median OS was 9.6 months and median PFS
was 5.1 months (Table 2). There were no significant differences in OS and PFS between
the subtypes. ENKTL showed the lowest median OS (5.1 months) and ALCL, ALK-
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revealed the worst median PFS (2.8 months). In the Kaplan-Meir analysis, Lugano stage,
IPI score ≥ 3, initial treatment response, and serum LDH elevation were significantly
associated with OS and PFS (Supplementary Figure S2). Initial treatment response was an
independent factor for OS (PD: HR 63.369, p < 0.001) and PFS (PD: HR 16.976, p = 0.001)
in multivariate analysis. Elevated serum LDH level (HR 5.045, p = 0.015) was also an
independent factor for OS (Table 4).
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ALCL, ALK- was mostly located in the stomach rather than the intestine and mani-
fested as a submucosal mass (Figure 4A), an ulcerofungating mass, or deep ulcer. Tumor 
cells were medium to large or pleomorphic and heterogeneous. Nuclear membranes were 
irregular and occasionally showed hallmark (kidney-shaped) cells and multinucleated 
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matory cells. Tumor cells were all diffusely immunoreactive for CD30 within the cyto-
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Figure 3. Intestinal T-cell lymphoma, not otherwise specified. Stomach endoscopy shows multiple
serpiginous-shaped superficial erosions with surface nodularity (A). Terminal ileum endoscopy
demonstrates several geographic shallow and deep ulcerations (B). Tumor cells show diffuse and
destructive growth (C). Some cases show medium to large atypical lymphoid cells with inflammatory
background (D) or large pleomorphic cells with eosinophilic cytoplasm (F). Tumor cells are CD3
positive and reveal no epitheliotropism (D).
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patients (76.3%) died of disease and 32 patients (84.2%) experienced disease recurrence or 
progression during the follow-up period. ALCL, ALK+ cases had no recurrence or death 
and were excluded from survival analysis. Median OS was 9.6 months and median PFS 
was 5.1 months (Table 2). There were no significant differences in OS and PFS between 
Figure 4. Anaplastic large cell lymphoma (ALCL). ALCL, ALK-negative (A,B). Endoscopically,
the esophagus shows a large elevated submucosal tumor covered with mucosal ulceration (A).
Biopsy findings demonstrate non-cohesive medium to large pleomorphic cells with irregular nuclei
(B). ALCL, ALK-positive (C–F). Endoscopy reveals hyperemic irregular and nodular surface with
abnormalities of surroundi g folds in the stomach (C). The same case shows large pleomorphic
lymphoid cells with eccentric n clei nd abundant cytoplasm in the neut ophilic background (D).
The tumor cells are immunoreactive for CD30 (cytoplasmic, nuclear membrane and Golgi region; E)
and ALK (cytoplasm and nucleus; F).
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Table 4. Cox proportional hazards regression model of primary gastrointestinal T/NK cell lymphoma.
Overall Survival Progression Free Survival
Variables Univariate Multivariate Univariate Multivariate
p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI)
>60 years 0.066 2.369 (0.953–4.350) - - 0.050 2.079 (1.001–4.318) - -
Male 0.728 1.141 (0.542–2.403) - - 0.424 1.335 (0.657–2.711) - -
Subtypes
ENKTL 0.831 1 (reference) - - 0.846 1 (reference) - -
MEITL 0.453 1.429 (0.563–3.626) - - 0.426 1.430 (0.593–3.450) - -
ITCL, NOS 0.960 1.009 (0.312–3.019) - - 0.762 1.175 (0.414–3.340) - -
ALCL, ALK- 0.602 1.397 (0.439–4.135) - - 0.488 1.480 (0.489–4.477) - -
Location
Esophagus 0.171 1 (reference) 0.383 1 (reference)
Stomach 0.563 1.856 (0.228–15.082) - - 0.496 0.477 (0.057–4.025) - -
Small intestine 0.504 2.012 (0.259–15.606) - - 0.434 0.437 (0.055–3.470) - -
Ileocecum 0.631 0.554 (0.050–6.174) - - 0.125 0.145 (0.012–1.707) - -
Large intestine 0.601 0.544 (0.055–5.326) - - 0.212 0.242 (0.026–2.249) - -
Multiple site 0.990 1.005 (0.453–2.228) - - 0.930 1.034 (0.493–2.170) - -
UGI involvement 0.404 0.715 (0.324–1.574) - - 0.282 0.651 (0.297–1.424) - -
GI complication 0.348 1.448 (0.668–3.139) - - 0.112 1.854 (0.865–3.971) - -
GI perforation 0.219 1.598 (0.757–3.376) - - 0.305 1.449 (0.713–2.945) - -
Tx with surgery 0.798 0.906 (0.425–1.930) - - 0.782 1.105 (0.545–2.242) - -
Lugano stage IV 0.051 2.214 (0.996–4.533) - - 0.041 2.119 (1.031–4.354) 0.299 0.461 (0.107–1.989)
IPI ≥ 3 <0.001 4.922 (2.022–11.979) 0.485 1.570 (0.442–5.581) 0.001 4.209 (1.846–9.597) 0.391 1.686 (0.511–5.556)
Elevated LDH 0.038 2.248 (1.045–4.835) 0.015 5.045 (1.365–18.654) 0.019 2.446 (1.155–5.718) 0.076 2.903 (0.894–9.424)
Elevated B2M 0.023 3.685 (1.194–11.368) 0.429 1.835 (0.407–8.273) 0.037 2.940 (1.066–8.108) 0.827 1.160 (0.308–4.369)
Initial Tx response
CR 0.001 1 (reference) 0.003 1 (reference) <0.001 1 (reference) 0.005 1 (reference)
PR 0.012 5.064 (1.418–18.079) 0.058 6.374 (0.940–43.236) 0.001 10.720 (2.56–44.84) 0.043 5.911 (1.061–32.928)
SD 0.385 2.611 (0.299–22.781) 0.429 2.662(0.235–30.093) 0.002 61.45 (4.58–824.33) 0.006 45.692 (3.12–790.67)
PD <0.001 24.554 (5.353–112.62) <0.001 63.369 (6.60–608.41) <0.001 24.22 (5.31–110.43) 0.001 16.976 (3.14-91.65)
ALCL, ALK-; anaplastic large cell lymphoma, ALK-negative, ALCL, ALK+; anaplastic large cell lymphoma, ALK-positive, B2M; beta-2 microglobulin, CI; confidence interval, CR; complete response, ENKTL;
extranodal NK/T cell lymphoma, nasal type, GI; gastrointestinal, HR; hazard ratio, ITCL, NOS; intestinal T-cell lymphoma, not otherwise specified, MEITL; monomorphic epitheliotropic intestinal T-cell
lymphoma, LDH; lactate dehydrogenase, PD; progressive disease, PR; partial response, SD; stable disease, Tx; treatment, UGI; upper gastrointestinal tract (esophagus and stomach). Statistically significant values
were boldfaced.
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4. Discussion
Primary GI-TNKL is a heterogeneous and rare disease group, and there are few ex-
tensive clinicopathologic studies including the entire GI tract ranging from the esophagus
to the large intestine. In the present study, we investigated clinicopathologic features of
38 Korean GI-TNKL cases. GI-TNKL accounted for 4.5% of all primary GI lymphomas.
This figure is somewhat less than the 13–15% frequency of GI-TNKL reported in East
Asia [1–4]. However, some of those studies included only the intestinal tract, unlike our
study that also included the stomach and esophagus. In the large-scale study of gastroin-
testinal tract lymphoma conducted at an institution in Southwest China, the frequency of
GI-TNKL was 12.9% [3]. In that study, gastric MALT lymphoma accounted for 15.5% of all
GI lymphomas, whereas in our cohort, it was much higher at 43.7%. That is, since gastric
MALT lymphoma is more common in South Korea than in other countries, the frequency
of GI-TNKL may be relatively low. When gastric MALT lymphoma was excluded, the fre-
quency of GI-TNKL rose to 8.1%.
In our cohort, GI-TNKL occurred in adults with a median patient age in the sixth
decade of life and a slight male predominance. The most common histologic type was
ENKTL, followed by MEITL, ITCL, NOS, ALCL, ALK-, and ALCL, ALK+. The small and
large intestines were the most affected regions. More than 90% of patients complained of
various GI symptoms and over half of patients suffered from GI complications. Half of
patients had surgical treatment, of which 47.4% underwent emergency operation. Half of
patients completely responded to initial chemotherapy, while about half of patients had
relapse or progression of the disease. These frequencies and characteristics are similar to
previous studies reported in the Asian region [1–3,11,12].
On initial endoscopic findings, 71.4% had mass lesions or deep ulceration and 23.8%
showed superficial ulcers. The single MEITL case that had nearly normal appearance
in endoscopy revealed intraepithelial lymphocytosis in histology. There were two other
cases that had lesions in the jejunum and they were clinically diagnosed by computed
tomography (CT) imaging instead of endoscopy. Since GI-TNKL, which occurs most
frequently in small intestine, may not show any specific findings on the endoscope, it is
crucial for early correct diagnosis to suspect this rare disease in patients complaining of
GI symptoms.
About 70% (9/13) of ENKTL showed NK cell phenotype (CD56-positive). In the re-
maining four cases, two cases were negative for both CD4 and CD8, and the other two cases
were focal positive for both CD4 and CD8. However, they were all positive for granzyme
B, suggesting cytotoxic T cell phenotype. Similarly, clonal TCR gene rearrangement was
observed in the two cases with T cell phenotype.
The level of circulating EBV DNA in blood is not included in the diagnostic criteria of
ENKTL, and EBV infection should be confirmed in tumor cells [5]. In addition, EBV posi-
tivity in tumor cells or blood is not always the same as the diagnosis of ENKTL, and may
occur in other T-cell lymphoma subtypes as well. In our cohort, EBV positivity in blood was
37.5% in ENKTL, 33.3% in MEITL, and 16.7% in ITCL (Supplementary Table S2). However,
since EBV DNA can be released from tumor cells into plasma, the level of circulating EBV
DNA is a reliable marker for tumor load and can be useful for monitoring disease activity
and predicting prognosis. High EBV DNA titers have been reported to be associated with
extensive diseases, unfavorable response to treatment, and low survival rates [13,14]. Al-
though the number of positive cases in this study was small and EBV DNA quantification
tests were performed in whole blood and not in plasma, the EBV DNA titer was at least
5 times higher in ENKTL than MEITL and ITCL. Three ENKTL cases with high EBV titer
were stage IV at the time of diagnosis, and two cases with follow-up data died within
2 months of chemotherapy.
MEITL was most frequently located in the jejunum (75%). There was a case of single
gastric lesion (8.3%) and a case of multiple large intestinal lesions (8.3%) without small
intestinal involvement. Gastric or colonic alone MEITL is rare and has been reported at
about 2.4% and 18%, respectively [15,16].
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In two previous studies, aberrant expression (heterogeneous and weak pattern) of
CD20 was reported in some MEITLs with frequencies of 24% and 11%, respectively [17,18].
However, no such aberrant expression of CD20 was observed in this study.
The revised fourth edition of the WHO classification of neoplastic disease of hematopoi-
etic and lymphoid tissue has newly categorized ITCL, NOS, which arises in the intestines
or sometimes other sites in the gastrointestinal tract and does not fulfill the criteria for
other T/NK cell lymphomas, including MEITL or ENKTL [5]. In our institution, primary
intestinal T cell lymphoma which cannot be categorized as a known entity has been diag-
nosed as PTCL, NOS. Most were located in the small intestine or ileocecum (71.4%) and the
remainder were in the stomach. Tumor cells were CD4+/CD8+ (80%) or CD4-/CD8- (20%).
Compared to other subtypes, ALCL was more often located in the upper GI tract and
GI complications were relatively less common. These patients underwent chemotherapy
rather than surgery. Although four of the five ALCL, ALK- cases were Lugano stage I or
II, the median OS and PFS were relatively shorter compared to other GI-TNKLs. ALCL,
ALK- is known to exhibit significant clinical and genetic heterogeneity. Chromosomal
rearrangements of DUSP22 or TP63 occur in about 30% and 8% of ALCL, ALK-, respec-
tively [19]. DUSP22-rearranged ALCLs are associated with favorable prognosis similar to
ALCL, ALK+, while TP63-rearranged ALCLs have very poor outcomes [19]. To predict the
clinical course of ALCL, ALK-, immunohistochemistry for p63 can be a useful screening
test [20]. It is highly sensitive for TP63 rearrangement but is not specific. TP63 rearrange-
ment must be confirmed by genetic methodology such as fluorescence in situ hybridization
(FISH) [20]. Unfortunately, due to the lack of adequate and available tissue, additional tests
to identify genetic subtypes were not conducted in this study.
Except for one case of ALCL, ALK+, disease recurrence or progression in patients
with GI-TNKL was common (84.2%). The prognosis was poor with a median survival of
9.6 months and median PFS of 5.1 months. OS and PFS showed no significant differences
among the histologic subtypes as in the previous study [2]. IPI score (≥3), serum LDH
or B2M elevation, and initial treatment response (PD) were associated with poor OS and
PFS. Among them, elevated serum LDH and initial treatment response (CR or PD) were
independent prognostic factors for OS. The initial treatment response (PR, SD, or PD) was
an independent prognostic factor for PFS. Although GI complications may affect mortality,
there was no statistically significant effect on prognosis. Since this study has a relatively
small number of cases, there may be some limitations in survival analysis.
Recent studies have shown the characteristic genetic alterations in GI-TNKL. Whole ex-
ome and next generation sequencing of six primary GI-ENKTLs showed mutations in JAK3
and the voltage gated potassium channels [21]. In MEITL, mutations of JAK1 and STAT5B,
genes related to the JAK/STAT signaling pathway, mutations in KRAS, a gene related to
the RAS signaling pathway, a loss-of-function mutation of SETD2, a chromatin modifying
gene, were found [21–23]. There is little research on the genetic alteration of ITCL to date.
In a previous study, JAK3, SETD2, and NRAS mutations have been reported in ITCL [21].
Therefore, ITCL is thought to share some similar genetic features with MEITL. Although
further robust studies are required, such genetic alterations might be promising with regard
to the treatment of GI-TNKL.
CHOP with or without etoposide has been most widely used regimen in our co-
hort. However, CHOP is no longer the standard choice for ENKTL treatment and it is
less effective in MEITL as well [24]. Concurrent or sequential chemoradiation therapy is
currently considered as the standard treatment for patients with localized ENKTL [25].
L-Asparaginase or pegylated asparaginase containing regimens are widely used in the
treatment of advanced and relapsed/refractory ENKTL [26,27]. Since the outcomes of
various treatment regimens currently used are still poor, several novel approaches targeting
for PD-1/PD-L1 [28], LMP1/LMP2 [29], and JAK/STAT pathway (NCT02974647) are being
conducted in ENKTL [30], and STAT5 [31,32] in MEITL. In ALCL, CHOP or CHOP plus
etoposide remains the first-line therapy [33] and recent clinical trials with anti-CD30 anti-
body (brentuximab vedotin) have shown substantial activity in the relapsed or refractory
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disease [34] and front-line treatment [35]. Autologous hematopoietic stem cell transplan-
tation as front line consolidation in PTCL, NOS, ALCL, ALK-, ENKTL (disseminated),
and enteropathy-associated T-cell lymphoma is recommended by expert consensus [36].
5. Conclusions
Primary GI-TNKL consisted of unique subtypes showing specific characteristics of
macroscopy, histology, immunophenotype, and prevalent anatomic subsites. Among them,
ENKTL and MEITL were relatively common. Cases with advanced Lugano stage, high IPI
score, or bowel perforation that required emergent operation were not uncommon. GI-
TNKL also showed aggressive behavior with short PFS and OS. Primary GI-TNKL is
difficult to diagnose due to its rarity, various subtypes, and histopathological features.
A thorough clinical and pathological descriptive analysis will be helpful for accurate
understanding, diagnosis, and treatment.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cancers13112679/s1, Methods: Immunohistochemistry. Table S1: First-line treatment of
primary gastrointestinal T/NK cell lymphoma. Table S2: The results of whole blood EBV quantitative
PCR test in patient with primary gastrointestinal T/NK cell lymphoma. Figure S1: Comparison of
clinical features of primary gastrointestinal T/NK cell lymphoma sub-types. Figure S2: Kaplan-Meier
survival curves according to clinicopathological parameters.
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